SCHEMBL17897232

SCHEMBL17897232

CC(C)N(C)CCN(C)c1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.50
CYP2C19 P33261 3/20 0.50
CHRM2 P08172 6/20 0.43
ADRA2A P08913 4/20 0.43
DRD1 P21728 4/20 0.43
SLC6A4 P31645 4/20 0.43
SLC6A3 Q01959 4/20 0.43
KCNH2 Q12809 4/20 0.43
HTR2A P28223 3/20 0.43
HRH1 P35367 3/20 0.43
SLC6A2 P23975 3/20 0.43
ADRA1A P35348 2/20 0.43
ADRA2B P18089 2/20 0.43
ADRA2C P18825 1/20 0.43
OPRK1 P41145 1/20 0.43
CHRM1 P11229 4/20 0.42
CHRM5 P08912 3/20 0.42
CHRM4 P08173 2/20 0.42
CHRM3 P20309 2/20 0.42
KDM4E B2RXH2 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4445537 0.82 CYP2D6 (0.72) CYP2D6CYP2C19CHRM2ADRA2ADRD1
SCHEMBL434743 0.78 CYP2D6 (0.56) CYP2D6CYP2C19CHRM2ADRA2ADRD1
SCHEMBL85721 0.77 CYP2D6 (0.55) CYP2D6CYP2C19CHRM2ADRA2ADRD1
SCHEMBL14748423 0.77 CYP2D6 (0.51) CYP2D6CYP2C19CHRM2ADRA2ADRD1
SCHEMBL1904189 0.77 CYP2D6 (0.55) CYP2D6CYP2C19CHRM2ADRA2ADRD1
SCHEMBL31490354 0.77 POLB (0.58) CYP2D6CYP2C19CHRM2ADRA2ADRD1
SCHEMBL844392 0.77 CYP2D6 (0.55) CYP2D6CYP2C19CHRM2ADRA2ADRD1
Hydrochloric Acid SCHEMBL5379223 0.77 CYP2D6 (0.55) CYP2D6CYP2C19CHRM2ADRA2ADRD1
SCHEMBL440638 0.77 POLB (0.58) CYP2D6CYP2C19CHRM2ADRA2ADRD1
SCHEMBL5779464 0.77 CYP2D6 (0.50) CYP2D6CYP2C19CHRM2ADRA2ADRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9676780-B2 Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2017-06-13 US disclosed
US-9676780-B2 Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2017-06-13 US disclosed
US-20160194330-A1 PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2016-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194330-A1 PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES ADORA2A, ADORA1, ADORA3 CYP2D6 1956/4885CYP2C19 2426/4885CHRM2 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.